key: cord-0050765-zif3ha9y
authors: nan
title: Full Issue PDF
date: 2020-09-28
journal: JACC Basic Transl Sci
DOI: 10.1016/s2452-302x(20)30389-2
sha: 7e682bc4a9fc37d6224dc6690e6379b6a07cbb27
doc_id: 50765
cord_uid: zif3ha9y

nan

Using serial analysis of myocardial gene expression employing endomyocardial biopsy starting material in a dilated cardiomyopathy cohort, we show that mRNA expression of the severe acute respiratory syndromecoronavirus-2 (SARS-CoV-2) cardiac myocyte receptor ACE2 is up-regulated with remodeling and with reverse remodeling down-regulates into the normal range. The proteases responsible for virus-cell membrane fusion were expressed but not regulated with remodeling. In addition, a new candidate for SARS-CoV-2 cell binding and entry was identified, the integrin encoded by ITGA5. Up-regulation in ACE2 in remodeled left ventricles may explain worse outcomes in patients with coronavirus disease 2019 who have underlying myocardial disorders, and counteracting ACE2 up-regulation is a possible therapeutic approach to minimizing cardiac dam- either due to myocarditis (5, 6) or myocardial dysfunction without evidence of inflammation (2) (3) (4) . The prevalence of cardiac complications in patients without underlying heart disease ranges from 20% to 30% (7) (8) (9) , which when present worsens prognosis. In the initial report of patients receiving intensive care, evidence of cardiac injury was associated with a 50% mortality compared with a <10% mortality without such evidence (3) .

The prognosis worsens further when evidence of myocardial injury is superimposed on pre-existing cardiovascular disease, with mortality rising to above 60% (3).

A well-established pathway by which the CoV-2 or the original SARS-CoV virus gains entry into cells includes membrane attachment by binding to angiotensin converting enzyme 2 (ACE2) (10, 11) , fusion of viral and cell surface membranes through the recruitment of host proteases (12) (13) (14) , and virus internalization followed by assembly of cytoplasmic membranous structures into replication vesicles (15) . In addition, there are other possible mechanisms of virus internalization such as binding to integrins (16, 17) , some of which also bind to ACE2 (18, 19) . Although CoV-2 or CoV cell internalization has been investigated in model systems (10) (11) (12) (13) (14) (15) and is beginning to be evaluated in the human heart (20) , it is unclear whether the virus enters human cardiac myocytes and whether the necessary biologic constituents are expressed in the heart. Of particular importance is the role of ACE2; in human ventricular myocardium, ACE2 is a highly functional enzyme present in cardiac myocytes (20) that breaks down angiotensin II to the counter-regulatory peptide angiotensin-(1-7) (21, 22) . In explanted human heart preparations from patients with end-stage heart failure with reduced (<0.50) left ventricular ejection fraction (HFrEF), ACE2 enzyme activity (22) as well as gene expression at the messenger ribonucleic acid (mRNA) (20, 23) and protein (20, 22) levels are upregulated compared with organ donor control subjects. This is potentially important because upregulated ACE2 might be a mechanism by which CoV-2 myocardial involvement is more prominent in patients with underlying heart muscle disease (20) .

However, it is unclear whether ACE2 is upregulated in intact hearts with less severe pathologic (awarded to Dr. Lowes), and K08 HL125725 (awarded to Dr. Kao); American Heart Association grant 16SFRN31420008 (awarded to Drs. Buttrick and Bristow); and an American Heart Association COVID-19 Rapid Response grant awarded to Dr. Bristow. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. remodeling/dysfunction than in explanted hearts from cardiac transplant recipients, who in contrast to most organ donor control subjects have been extensively treated with renin-angiotensin system (RAS) inhibitors that may affect ACE2 expression (24, 25) . In addition, it is not clear whether the proteases that prime and facilitate membrane fusion are expressed or regulated in the remodeled, failing human heart.

Finally, there is limited information on the status of integrins, particularly those that can bind to ACE2 or to the CoV-2 virus itself, to potentially effect viruscell internalization (16) . To obtain information on these mechanisms in nonfailing (NF) and remodeled intact human hearts, we analyzed data from a serial analysis of myocardial gene expression cohort study (26) , where reverse remodeled left ventricles (LVs) were compared with unchanged ventricles exposed to the same pharmacologic regimen. terial only, as previously described (26, 27) (27) and the 3 groups, who had in common Table S1 ) (26, 28) . LVEF was measured by radionuclide single-photon emission computed tomography imaging as previously described (27, 29) , and a reverse remodeling responder (R) in the entire 46-patient F/NDC cohort was defined as an LOCF increase in LVEF of $5 absolute percent at 3 months or $8% at 12 months (26, 27) . Nonresponders (NRs) were subjects who did not meet these LVEF change criteria. EmBx and right heart catheterization were performed as previously described (26, 27) , and there were no procedurerelated complications.

All patients signed written consent for this multicenter study conducted at the University of Colorado Anschutz Medical Campus and the University of Utah Medical Center. The study included a data and safety monitoring board and was approved by the institutional review boards at both sites.

RNA EXTRACTION AND mRNA EXPRESSION MEASUREMENTS. RNA extraction was performed as previously described (26, 27) . All individual patient mRNA measurements were from the same RNA extraction, typically involving 2 to 5 separate EmBx samples per study. Extracted RNA was stored at À80 C until use, and microarray and RNA-Seq methodologies were as previously described (26) .

Microarray gene expression data were normalized by log-scale robust multi-microarray analysis to yield output in fluorescence intensity on an exponential scale. RNA-Seq data transcript levels were quantified Dynamic Regulation of SARS-CoV-2 Binding and Cell Entry Mechanisms as fragments per kilobase of exon per million mapped reads, as previously described (26) . Fold change or fold difference was calculated by log 2 transformation as described (26) .

DATA ANALYSIS AND STATISTICAL TESTS. We used both baseline comparisons between NF control subjects and patients with F/NDC plus changes from baseline in patients with F/NDC to construct an ordered classification of 4 degrees of remodeling association (Supplemental Appendix, Supplemental Table S2 ), in serially evaluated patients with F/NDC these results were then linked to the reverse remodeling mRNA results measured by both the microarray and RNA-Seq platforms. The estimated alpha levels based on achieving p < 0.05 in more than 1 condition including directionality requirements are given in the Supplemental Appendix (Supplemental Table S2 ): unequivocal evidence, 0.0001; evidence, 0.002; and possible evidence, 0.08.

The statistical significance of all gene expression data was analyzed in the same way, by nonparametric methods using Wilcoxon rank sum or signed rank tests. Correlation analysis was by Spearman rho LVEF data for which evidence of non-normal distribution was absent (26) , and baseline characteristics were analyzed by Student's t-tests or contingency table analysis.

Because several analyzed gene expression groups had small counts (NF, n ¼ 4; RNA-Seq, n ¼ 6 R and 6 NR; LOCF 3-month F/NDC, n ¼ 5 Rs and 3 NRs) we used mean AE SD or, for change values, SEM as estimates of central tendency and dispersion, in both the small count groups and larger groups to which these data were compared. For microarray data (30 R and 16 NR), group size was sufficient for data to be also presented as median (interquartile range [IQR] Table S1 ), and follow the same pattern, except that the LVEF change from baseline was larger than in the entire cohort ( Figure 2 contains F/NDC versus NF baseline mRNA abundance data, for ACE2, 2 associated RAS genes (AGT and ACE), and 5 proteases that have been implicated in CoV-2 or CoV-2-cell membrane priming and fusion (12) (13) (14) 31, 32) . Compared with NF control subjects, ACE2 is substantially up-regulated in F/NDC, by 1.97fold (p ¼ 0.008). ACE expression is unchanged from control, as is angiotensinogen. The angiotensin II type 1 and type 2 receptors (AGTR1, AGTR2) are plotted in Figure 3 and are not different between NF and F/NDC. None of the proteases shown in Figure 2 (27) . NPPB was upregulated by 8.8-fold in F/NDC, and its expression versus that of ACE2 was significantly related (Spearman rho ¼ 0.73; p < 0.0001). Unlike in previous studies using reverse transcriptase PCR (26, 27, 33, 34) , MYH6 was unchanged between NF and F/NDC but was markedly up-regulated on reverse remodeling ( Table 2 ) consistent with previously reported data (26, 27, 34) . I n t e g r i n s . Table 3 contains NF versus F/NDC baseline data for 10 integrins previously reported to bind to ACE2 (18, 19) , facilitate viral internalization (17) , or be associated with LV remodeling (35) or cardiac myocyte injury protection (36) . Only 1, the laminin binding integrin ITGA7, has not been reported to be involved in pathogenic virus cell internalization. Five integrins in Table 3 bind to the arginine-glycineaspartic acid (RGD) motif, recently identified in the CoV-2 spike protein binding domain (16) and used by multiple viruses for binding to integrins. Of the ACE2 binding integrins, ITGA5 expression was 1.28-fold higher in patients with F/NDC compared with NF control subjects (p ¼ 0.039), whereas ITGB1 and ITGA2 were not different. ITGA5 has also been associated with virus internalization (17) and LV remodeling where it decreases with LV assist device treatment (35) . Of the 6 non-ACE2 binding integrins listed in Table 3 that have been associated with virus internalization, 4 reached a p value of <0.05 for differences between patients with F/NDC and NF control subjects, 2 up-regulated (ITGB3 and ITGA4) in patients with F/NDC and 2 down-regulated (ITGB6 and ITGA6). For the 3 genes previously associated with remodeling other than ITGA5, 2 (ITGA6 and ITGB6) were down-regulated in patients with F/NDC consistent with the decreased expression of ITGA6 in human LVs with dilated cardiomyopathies (35) , or the up-regulation previously reported with LV assist device treatment (35) . The laminin binding integrin ITGA7 was up-regulated in patients with F/NDC.

REMODELING. ACE2, other RASs, and proteases. Changes in R or NR fold changes based on mean values are given in Table 2 Table S3 ). Although in the R versus NR comparison, PRSS1 was down-regulated on reverse remodeling (fold change: 0.90; p ¼ 0.042) (Supplemental Table S3 ) the change was related to an up-regulation in the NR group rather than a change in the R group. AGTR1 met criteria for possible evidence (p < 0.08) for an association with remodeling, with R and not NR up-regulation on microarray measurements. RNA-Seq data exhibited a decrease in ACE2 expression on reverse remodeling (p ¼ 0.004), with a greater fold change of 0.40-fold (approximate 2.5fold decline) than in microarray data. Thus, ACE2 met criteria for unequivocal evidence (p < 0.0001) of a remodeling association. RNA-Seq data for all other RAS and protease genes ( Table  2,   Supplemental Table S4 ) were similar to microarray measurements.

Bristow et al. Table 2 and   Supplemental Table S4 ). NPPB, which encodes a precursor of a counter-regulatory peptide considered the premier biomarker of pathologically remodeled ventricular myocardium in tissue (27, 34) or plasma (37) , exhibited expression behavior very similar to ACE2 including an unequivocal evidence rating for remodeling association. MYH6, PLN, and ADRB1 all had remodeling associated ratings of evidence (p < 0.002), whereas ATP2A2 rated possible evidence.

I n t e g r i n s . Reverse remodeling changes in integrins are given in Table 2 and Supplemental Table S4 . For the p < 0.05 baseline-changed genes, ITGB3, ITGB6, and ITGA5 had at least 1 platform showing significant change on reverse remodeling and thus qualified for evidence of a remodeling association ( Table 3) . Figure 4 illustrates the positioning and role of ACE2 within the renin-angiotensin-aldosterone system. In the human LV, this zinc-dependent carboxypeptidase catalyzes the conversion of the octapeptide angiotensin II to the counter-regulatory heptapeptide angiotensin-(1-7) with high activity and efficiency (21) . ACE2 exerts a very important function in the heart, by reducing levels of angiotensin II as well as by generating a counter-regulatory peptide that activates MAS1 receptor pathway signaling through G q and multiple downstream events including reducing extracellular signal related kinase 1/2 MAP kinase activation (38, 39) . We found that in a setting where RAS inhibitors were not a potentially confounding variable ACE2 mRNA expression was substantially upregulated in intact failing/remodeled ventricular myocardium, confirming and extending previous work in explanted human hearts (20, 22, 23) . From its up-regulated expression in F/NDC at baseline, with reverse remodeling ACE2 then down-regulated toward control values in measurements by both mRNA However, ACE2 is an important counter-regulatory enzyme in the heart, responsible for converting angiotensin II to angiotensin-(1-7) that is antiproliferative, antifibrotic, and a vasorelaxant. Based on gene ablation, ACE2 is considered an "essential regulator of heart function" (53) . It follows that any ACE2 inhibitor would need to block CoV-2 binding without decreasing enzyme activity, which may be possible through antibody inhibition (11) or the use of decoy receptors (54) . Another possibility would be to deploy an ACE2 activator such as diminazene (55) In normal hearts, there is baseline angiotensin-converting enzyme 2 (ACE2) expression, which functions as both an enzyme in the reninangiotensin system and as the internalizing receptor for SARS-CoV-2 virus. Proteases such as TMPRSS2 typically act as the co-receptor.

However, in dilated cardiomyopathy (DCM), there is 2-fold up-regulation of ACE2 and potential co-receptor integrin a-5 (Ia-5, which is a product of the ITGA5 gene). In patients who respond to b-blockade, there is a reduction of ACE2 gene expression to normal levels, together with ITGA5 and integrin expression and reverse remodeling. LVEF ¼ left ventricular ejection fraction; MRA ¼ mineralocorticoid receptor antagonist.

from patients with end-stage heart failure with multiple comorbidities and complex drug regimens. The increased ACE2 expression most likely represents a compensatory mechanism to counterbalance the increase in RAS activity in progressive heart failure.

This would also support, although not demonstrate directly, that the shedding of ACE2 in the circulation is a consequence of increased receptor turnover and not the exhaustion of ACE2 in the myocardium. Thus, increased circulating ACE2 levels likely reflect increased tissue ACE2 levels. expression. This also indicated that ACE2 upregulation is not inherent to DCM, but is a response to its secondary RAS activation. COVID-19 has exposed many of the weaknesses of our cardiovascular patients and also issues within our health system. Careful rethinking of our strategies of prevention and mitigation of these cardiovascular conditions will not only help our patients but our health system and society at large. 

Our objectives were to determine whether autotaxin (ATX) is transported by lipoprotein(a) [Lp(a)] in human plasma and if could be used as a biomarker of calcific aortic valve stenosis (CAVS). We first found that ATX activity was higher in Lp(a) compared to low-density lipoprotein fractions in isolated fractions of 10 healthy participants. We developed a specific assay to measure ATX-Lp(a) in 88 patients with CAVS and 144 controls without CAVS. In a multivariable model corrected for CAVS risk factors, ATX-Lp(a) was associated with CAVS (p ¼ 0.003). We concluded that ATX is preferentially transported by Lp(a) and might represent a novel BINDING ASSAY. High-binding capacity microtiter 96-well plates (polystyrene, Greiner Bio-One) were coated overnight at 4 C with recombinant ATX (5 mg/ml) in carbonate buffer. Excess material was removed, and plates were blocked with PBST-1% BSA (150 ml/well) for 1 h. After washing, increasing concentrations of PBST-diluted apo(a) (0.05 mM to 1 mM; 100 ml/well) were added and incubated for 2 h at room temperature. After washing, apo(a) antibody (1 mg/ml, 100 ml/well) was added for 1 h at room temperature, followed by the secondary horseradish peroxidaseconjugated antibody for 45 min (1/10,000 dilution; 100 ml/well). Following PBST-1% BSA washes, absorbance was read at 405 nm. Purified apo(a) was obtained following the previously described method (20) . Plasmid encoding a 17-kringle-containing form of recombinant apo(a) was constructed and transfected into human embryonic kidney (HEK 293) cells as previously described (20, 21) . Recombinant-apo(a) was purified from the conditioned medium of stably-expressing cell lines by lysine-Sepharose (GE Healthcare, Chicago, Illinois) affinity chromatography as previously reported (20) . Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs). Logistic regression was used to determine the respective contribution of ATX-apo(a) and body mass index (BMI) based on the cutpoints that were identified by sensitivity and specificity analyses (area under the receiveroperating characteristic curve for CAVS presence).

Spearman's correlation coefficient (rs) was used to compare 2 continuous variables. Statistical analyses were performed using JMP software (V.14). A p value #0.05 was considered statistically significant.

LP (A) . We first undertook to establish a reliable and reproducible method for LDL and Lp(a) fraction separation validated using the Sebia Hydragel results ( Figure 1A) . To investigate the preferential association of ATX with Lp(a), we measured ATX activity in isolated fractions of LDL and Lp(a) from healthy participants. ATX activity was significantly higher in Lp(a) compared to the LDL fraction ( Figure 1B ). In addition, LysoPA content was also significantly higher in the Lp(a) fraction compared to the LDL fraction ( Figure 1C ).

Although a physical association between Lp(a) and ATX has been previously reported, it is presently unknown whether the interaction occurs within the LDL component or with apo(a). By using recombinant ATX coated in 96 well plates we assessed using a binding assay the interaction with purified apo(a). In this assay, we observed a dose-dependent interaction with a plateau at a concentration of w1,000 nM of apo(a) (Figure 2 ).

PLASMA. Having established that ATX activity is higher in isolated Lp(a) fractions, we sought to establish a quantitative assay to measure ATX-apo(a) in the plasma. We developed a capture assay to measure ATX bound to apo(a) and apoB (see Methods). In 232 subjects, including control and CAVS cases ( Table 1) , we found that the distribution of both ATX-apo(a) and ATX-apoB were skewed to the left ( Figure 3 ). ATX-apo(a) correlated significantly (rs ¼ 0.553; p < 0.0001) (Spearman correlation) with ATX-apoB, but not with Lp(a) or total ATX level measured by ELISA ( Figure 4 ). inhibitors, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) was also higher in the CAVS group. Also, patients with CAVS had higher levels of ATX-apo(a). Levels of circulating ATX and ATX-apoB were similar between the 2 groups.

For ATX-apo(a), we selected a cutpoint to simultaneously maximize the sensitivity and specificity (area under the receiver-operating characteristic curve) of the model. This was not done for ATX-apoB because we found no difference between CAVS case and controls. In a multivariable model (model 1), corrected for age, sex, BMI, T2D, hypertension, pharmacotherapy (calcium channel blockers and statins), HDL-C, and corrected LDL-C, we found that circulating ATX-apo(a) was associated with CAVS ( Table 2) . In a second model (model Finally, we sought to determine whether patients with T2D had higher or lower levels of ATX-apo(a) or ATX-apoB compared to patients without T2D and found no differences. We also separated our study population according to BMI and according to the adiponectin-to-leptin ratio (equal or above versus lower than top tertile) and again, we found no differences (data not shown).

Over the past 5 years, a series of genetic association, observational, and mechanistic studies have provided evidence that Lp(a) may represent a causal risk factor for CAVS. The mechanisms through which Lp(a) causes CAVS remain elusive. In this study, we aimed to The combination of an elevated ATX-apo(a) and an elevated BMI was associated with CAVS. Although additional studies will be needed to confirm these findings, this analysis suggests that ATX-apo(a) may represent a potential link between obesity, Lp(a), and CAVS and a new biomarker of CAVS risk.

ATX was first identified as a motility factor in tumorigenesis (22, 23) . It is a secreted glycoprotein that belongs to the ectonucleotide pyrophosphatase/ phosphodiesterase (NPP) family. ATX converts LysoPC into LysoPA, which promotes cell motility, inflammation, fibrosis, and calcification (24, 25) . Several tissues or organs may contribute to circulating levels of ATX or LysoPA. Adipose tissue-specific deletion of ATX resulted in a 40% reduction of plasma LysoPA levels (26) (27) (28) . Rancoule et al. (29) have also reported evidence that ATX expression is considerably higher in the visceral adipose tissue of obese compared to non- obese individuals. We have also reported that bariatric surgery is associated with reduction in ATX plasma levels in patients with severe obesity (30) . In addition, 2 large prospective studies (24) have reported that excess body weight and abdominal obesity were associated with CAVS incidence.

Lp(a) is an important carrier of oxidized phospholipids (OxPLs). LysoPA, which is also generated during the oxidation of lipoproteins [LDL or Lp(a)] (31-33), is a bioactive lipid that promotes a pro-inflammatory state and drives the mineralization of the aortic valve (14) .

In human explanted CAVS tissues, ATX activity and LysoPA levels were increased by several-fold compared to noncalcified aortic valves (14) . The proinflammatory effect as well as the mineralization associated with LysoPA occurs through an RHOA/ NF-kB/ bone morphogenetic 2 (BMP2) pathway (13) . In to be used as a CAVD biomarker, particularly in obese patients. Autotaxin was previously proposed as a CAVD biomarker in conjunction with lipoprotein(a), but this assessment produced mixed results that both supported (2) and found no association (1) with autotaxin abundance and CAVD risk. The reason for these seemingly inconsistent findings is unclear. One possible explanation might be that autotaxin activity is a key factor to assess rather than protein abundance (1) . In the current study, autotaxin activity was found to associate with CAVD risk, whereas in another 2020 study (1) that did not examine autotaxin activity, no association was seen with autotaxin abundance and CAVD risk. Future studies will be needed to assess autotaxin activity in larger patient populations to clarify these contrasting findings. (6), and it has become clearer that women who experience premature or early-onset menopause have a greater risk of cardiovascular mortality (7).

We have previously shown that the long-term absence of ovarian hormones in the guinea pig leads to detrimental changes to intracellular Ca 2þ regulation in the heart, resulting in the formation of a proarrhythmic substrate (8) . Studies on mice support the idea of Ca 2þ dysregulation following ovariectomy (9, 10) , and, in rats, it has been shown that estrogen can reduce incidence of arrhythmia following episodes of ischemia reperfusion (11) .

Postmenopausal women are more vulnerable to arrhythmia-related sudden cardiac death compared with pre-menopausal women (12) .

It is important to understand why these sex differences arise because prevention and management of cardiovascular disease may benefit from sexspecific approaches.

The aim of this study was to characterize the influ- (17) and custom macros (16), with the detection criteria set to 4.2 standard deviations (SDs) above the mean background value. Spark frequency, amplitude, fullwidth at half maximum (FWHM), and full-duration at half maximum (FDHM) were measured. Spark mass was calculated as previously described (18). [CI] with "n" being the total number of cells from "N" the total number of hearts (n/N ¼ cells/hearts). The p value determined to be statistically significant is p < 0.05. The notation describing p values is as follows:

*p < 0.05, **p < 0.01, and ***p < 0.001, and when comparisons were made with the ACOV group, the notation describing p values is zp < 0.05, zzp < 0.01, and zzz p < 0.001. The number of animals in each group were Sham ¼ 9, AC ¼ 9, ACOV ¼ 6, and ACOVþE ¼ 6. Values are mean AE SD. Heart weight (HW), lung weight (LW), uterine weight (UW), body weight (BW), and serum (E2) 17b-estradiol. In vivo M-mode echocardiography measurements of the left-ventricle internal diameter end diastole (LVIDd) and end systole (LVIDs). Fractional shortening (FS) was significantly reduced in all 3 failing groups compared with Sham and was further reduced in ACOV compared with the AC (AEE) groups. The notation describing p values is as follows: *p < 0.05 and †p < 0.001 when comparisons were made with the Sham group. When comparisons were made with the ACOV group the notation describing p values is ‡p < 0.05.

AC ¼ aortic constriction; ACOV ¼ aortic constriction with ovariectomy; ACOVþE ¼ aortic constriction with ovariectomy supplemented with 17b-estradiol.

Firth et al. Fisher post hoc test: *p < 0.05, **p < 0.01, ***p < 0.001). Bars show mean (95% confidence interval). AC ¼ aortic constriction;

ACOV ¼ aortic constriction with ovariectomy; ACOVþE ¼ aortic constriction with ovariectomy supplemented with 17b-estradiol. Figure 1D ).

Caffeine-induced Ca 2þ transient protocols (14) were used to differentiate the rates of the cytosolic Ca 2þ removal mechanisms ( Table 2) . Sarco/endoplasmic reticulum (SERCA) function significantly decreased following AC and remained low in all AC groups compared with myocytes isolated from Sham.

When the SR was removed from Ca 2þ regulation, the rate of Ca 2þ decline remained unaltered among groups ( Table 2) .

As there is evidence that RyR2-mediated Ca 2þ release is altered in heart failure 

We have shown that pressure overload and the long-term absence of ovarian hormones results in changes to intracellular Ca 2þ regulation. Intracellular Ca 2þ regulation is intertwined with intracellular Na þ regulation; therefore, we investigated to determine whether important Na þ efflux and influx routes, known to be altered in heart failure, were affected by ovarian hormone withdrawal. We measured the Na þ /K þ ATPase current and the late Na þ current (I Na,Late ) in myocytes isolated from each experimental cohort.

The protocol for these experiments is illustrated in Figure 4A and is described in detail in Ke et al. (14) .

Briefly, the Na þ /K þ ATPase was inhibited by Values are mean AE SD. The function of SERCA significantly reduced following 150 days AC and was further reduced in myocytes from ACOV compared with Sham and AC, respectively. The rate of NCX remained unaltered among groups but contributed more toward Ca 2þ efflux in the AC groups compared with Sham. The notation describing p values is as follows: *p < 0.001, when comparisons were made with the Sham group. When comparisons were made with the ACOV group, the notation describing p values is †p < 0.05, and ‡p < 0.01.

AC ¼ aortic constriction; ACOV ¼ aortic constriction with ovariectomy; ACOVþE ¼ aortic constriction with ovariectomy supplemented with 17b-estradiol; NCX ¼ Na þ/ Ca 2þ exchange; SERCA ¼ sarco/endoplasmic reticulum Ca 2þ -ATPase Firth et al. Estrogen Modulates Cell Responses in Heart Failure superfusion of the cells in K þ -free solution for 2 min, during which time intracellular Na þ concentration will increase. After 2 min, the superfusate was switched to normal Tyrode's solution that contained 6 mM K þ . This reactivates the Na þ /K þ ATPase, which extrudes the accumulated Na þ from the cell, and the rate of extrusion was used to assess its function.

Steady-state Na þ /K þ ATPase current density was taken as the difference between the holding current in the presence and absence of K þ . The Na þ extrusion rate (typical changes in current are shown Figure 4A ) was significantly reduced in AC groups compared with Sham (p < 0.001), and myocytes from ACOV were characterized by a further reduction in extrusion rate, compared with the AC group, respectively (p < 0.05) ( Figure 4B ). The Na þ /K þ ATPase current density was reduced by approximately 50% in all AC groups compared with myocytes from Sham (p < 0.001) ( Figure 4C ). LATE NA D CURRENT. Myocyte transmembrane potential was initially clamped at -120 mV before stepping the membrane potential to -20 mV for 2 s to elicit the I Na,Late , as shown in Figure 4D . The ranolazine-sensitive I Na,Late was measured 215 ms following the voltage step (27) and compared among groups. Myocytes from the AC groups were collectively characterized by an approximate 100% increase in I Na,Late compared with the Sham group (p < 0.001).

The ACOV group had the largest I Na,Late compared with AC and the ACOVþE groups (p < 0.001), and this result was consistent with the increase in charge density, as shown in Figure 4E . Inactivation of the Knowledge of the underlying mechanisms is scant and much more exploration will be required to improve our understanding of them (37) . There is evidence that they may involve estrogen receptor a is undoubtedly caused by the enhanced leak that may be spark mediated or by other routes (48) .

Activated exchange current may contribute to the action potential prolongation and may increase the potential for re-excitation. A key feature of heart failure is prolongation of the cardiac action potential, and we have suggested in this animal model that an increase in Na þ influx via I Na,late is involved (14) .

Strikingly, the absence of estrogen in heart failure further increases I Na,late and further prolongs the APD compared with heart failure when estrogen is pre- 

MHD associated with obesity, diabetes, and/or metabolic syndrome is an important precursor of HFpEF.

Mice fed a HFHS diet develop MHD with myocardial hypertrophy, fibrosis, diastolic dysfunction, and impaired energetics.

Mice on HFHS diet were treated with matched doses of VAL or sac SAC/VAL for 16 weeks.

Only SAC/VAL prevented diastolic dysfunction and fibrosis, and to a lesser extent oxidative stress, whereas VAL and SAC/VAL had similar effects on hypertrophy and energetics.

Neprilysin inhibition exerts beneficial effects on MHD that are complimentary to VAL, suggesting that SAC/VAL has promise to prevent the development of HFpEF in patients with or at risk for MHD.

Mice with obesity and metabolic heart disease (MHD) due to a high-fat, high-sucrose diet were treated with placebo, a clinically relevant dose of sacubitril (SAC)/valsartan (VAL), or an equivalent dose of VAL for 4 months. There were striking differences between SAC/VAL and VAL with regard to: 1) diastolic dysfunction; 2) interstitial fibrosis; and to a lesser degree; 3) oxidative stress-all of which were more favorably affected by SAC/VAL. SAC/VAL and VAL similarly attenuated myocardial hypertrophy and improved myocardial energetics.

In mice with obesity-related MHD, neprilysin inhibition exerts favorable effects on diastolic function. were measured as we have described (12) .

AND HIGH-ENERGY PHOSPHATES BY 31 Immunohistochemistry was performed as we have described (9) . Universal Mini kit (Qiagen, Hilden, Germany).

Capacity RNA-to-cDNA kit (Invitrogen, Carlsbad, California). Quantitative real-time polymerase chain reaction was performed using TaqMan reagents and probes for collagens Col1a1 and Col3a1 (Invitrogen).

Relative mRNA expression was normalized to 18s using the DDC T method. Neprilysin Inhibition in Metabolic Heart Disease statistical significance of differences within the same group was determined via paired Student's t-test. Table 1 ). VAL and SAC/VAL attenuated diet-induced LV hypertrophy to a similar extent. LV end-diastolic dimension was not affected by the HFHS diet, and was not affected by VAL or SAC/VAL ( Figure 2C) . LV end-systolic dimension and LV fractional shortening were not affected by diet, and neither was affected by VAL or SAC/VAL ( Figures 2D and 2E) . Figure 3A) . Likewise, wall motion during diastole (E m ) was decreased by HFHS diet ( Figure 3B) . VAL had no effect on E m , whereas SAC/VAL prevented the diet-induced decrease. As expected, E/E m was increased by HFHS diet, indicative of an increase in left atrial pressure. VAL did not significantly affect the E/E m ratio, whereas SAC/VAL prevented the dietinduced increase ( Figure 3C ). Values are mean AE SEM, unless otherwise indicated. n ¼ 4 to 6. LV function and high-energy phosphates ( 31 P nuclear magnetic resonance spectroscopy) were measured simultaneously in an isolated retrograde-perfused Langendorff heart preparation. *p < 0.05 vs. CD; †p < 0.05 vs. HFHS; ‡p < 0.05 vs. the respective baseline value.

ATP ¼ adenosine triphosphate; EDP ¼ end-diastolic pressure; PCr ¼ phosphocreatine; RPP ¼ rate  pressure product; other abbreviations as in Table 1 .

High-energy phosphates were measured in the beating heart by 31 (19, 20) . Similarly, we previously used 31 Rather, it more likely approximates early stages of MHD, and therefore whether these findings will translate to humans with more advanced disease is unclear. Another important consideration is that the mice in this study were started on treatment at the same time the diet was initiated. Therefore, the data presented reflect the use of these medications as a preventative rather than as a treatment strategy. 

Fibrotic remodeling of the heart in response to injury contributes to heart failure, yet therapies to treat fibrosis remain elusive. Yes-associated protein (YAP) is activated in cardiac fibroblasts by myocardial infarction, and genetic inhibition of fibroblast YAP attenuates myocardial infarction-induced cardiac dysfunction and fibrosis. NONREPERFUSED MI. Permanent left anterior descending coronary artery occlusion was used to induce MI, as previously described (11) . Briefly, the left coronary artery was located, and a suture was passed under the artery. To occlude the artery, a short length of tubing was threaded through the suture ends, and occlusion was affected by placing tension on the suture such that the tube compressed the artery. Ischemia was confirmed by electrocardiography change (ST-segment elevation). For sham operation, the same protocol was followed; however, no ligation of the coronary artery was performed.

AngII/PHENYLEPHRINE TREATMENT. Chronic AngII/ phenylephrine (PE) infusion was attained by using osmotic mini-pumps (Alzet, Durect Corporation, Cupertino, California) that were implanted subcutaneously in 8-to 10-week-old mice under anesthesia (2.5% Avertin, 12 ml/g body weight). AngII (288 mg/kg/day) with PE (100 mg/kg/day) was delivered for 2 weeks as previously described (16) . Control groups received vehicle infusion.

CELL-BASED STUDIES. Primary neonatal rat cardiac fibroblasts (NRCFs) and human ventricular fibroblasts were cultured as described elsewhere (7, 17) . Adenoviral transduction, transfection, luciferase reporter assays, chromatin immunoprecipitation, immunoblotting, immunostaining, quantitative polymerase chain reaction, and collagen gel contraction assays were performed using primary cells.

STATISTICAL ANALYSIS. All data are reported as mean AE SEM. Evaluation between 3 or more groups was performed by using one-way analysis of variance.

Post hoc multiple pairwise comparisons were performed by using Tukey's test. Student's t-test was used to evaluate the difference in means between 2 

To determine YAP activation in response to stress, primary NRCFs were stimulated with AngII. We observed a significant decrease in both YAP and large tumor suppressor kinase 2 (Lats) phosphorylation, indicating YAP activation ( Figures 1A and 1B) . AngII also increased YAP nuclear localization and YAP target gene expression in cardiac fibroblasts ( Figures   1C and 1D) . AngII treatment activated RhoA, and inhibition of RhoA with C3 toxin attenuated AngIIinduced YAP nuclear localization and TEAD luciferase reporter gene activation ( Figures 1E to 1G ). In addition, expression of activated RhoA was sufficient to activate YAP ( Figures 1H and 1I ). Together, these data indicate that RhoA mediates AngII-stimulated YAP activation in cardiac fibroblasts.

To determine YAP activation status in vivo, we injected wild-type C57Bl/6J mice with AngII, isolated hearts after 1 h, and generated cardiomyocyte and nonmyocyte-enriched fractions. Fraction purity was determined by expression of cardiomyocyte-specific and fibroblast-specific markers, troponin T, and platelet-derived growth factor receptor (PDGFR)-a, respectively. AngII treatment increased YAP activation, as determined by phosphorylation, as well as YAP target gene expression, in fibroblast-enriched fractions, indicating that AngII activates YAP in vivo ( Figures 1J and 1K) . Conversely, knockdown of endogenous YAP significantly down-regulated these genes (Figures 2A and   2B ). Increased de novo expression of a-SMA is a marker of the myofibroblast phenotype. YAP expression caused a significant increase in a-SMA protein levels ( Figures 2C and 2D ). Our data also show that aSMA-positive cardiac fibroblasts were increased by AngII treatment, and this outcome was significantly attenuated in YAP-depleted cells (Figures 2E and 2F) .

We also assayed the ability of fibroblasts to contract a collagen lattice in response to YAP overexpression and found it was significantly enhanced ( Figures 2G and 2H) . We performed chromatin immunoprecipitation in NRCFs using anti-YAP antibody and observed enrichment of YAP at this predicted TEAD-binding site ( Figure 3F) , indicating MRTF-A gene occupancy.

Luciferase assays were performed by using the endogenous 1 kb region proximal to exon 1 of the rat Mkl1 gene to drive reporter gene expression ( Figure 3G) . We tested the wild-type sequence, as well as 2 different mutant constructs that were generated by targeting TEAD-binding sites 1 and 2. Overexpression of YAP was sufficient to enhance luciferase expression using the wild-type construct;

however, YAP-induced reporter gene expression was prevented in both mutant constructs ( Figure 3H ).

Similar results were obtained with AngII treatment,

indicating that both sites are necessary for reporter gene induction ( Figure 3I ). In addition, YAP knock- (Figures 4D to 4I) .

These data indicate a fundamental role for MRTF-A in YAP-mediated responses.

DIFFERENTIATION. Importantly, we determined YAP function in primary adult human ventricular fibroblasts. Our findings show that AngII activated YAP in human cardiac fibroblasts (Figures 5A and 5B) . Treatment with AngII also up-regulated mRNA expression of Col1a1, Col3a1, Tgfb1, and aSMA, which was prevented by verteporfin, indicating YAP-TEAD dependence ( Figures 5C to 5F ). YAP expression was sufficient to increase pro-fibrotic gene expression, as well as MRTF-A and a-SMA mRNA and protein in human cardiac fibroblasts (Figures 5G to 5J) . In addition, this response was attenuated by CCG-203971, indicating that MRTF-A is an important target of YAP to mediate myofibroblast differentiation in human cardiac cells (Figures 5K to 5N ).

VIVO ATTENUATES FIBROSIS AFTER MI. We next investigated how loss of fibroblast YAP expression affected collagen deposition in the heart after injury.

We found that YAP was activated in fibroblastenriched heart fractions after 3 days of nonreperfused MI (Figures 6A and 6B) . (Figures 6I and 6J) .

Analyses using Col1a1 CreERT (Yap F/F ;Col1a1 CreERT ) to remove YAP expression in cardiac fibroblasts (21) yielded similar results to those observed in Studies regarding YAP function in lung (22), liver (23) , and kidney (24) response factor (SRF) (16, 18, (26) (27) (28) (11, 12) and reinforces the importance of cell type specificity of signaling in the heart.

The current study reports a relatively mild MI as determined by left ventricular functional decline, chamber dilation, and scar size. Although we determined the initial infarct, and found no differences between control mice and YAP-targeted mice (Supplemental Figure 5 ), it is difficult to directly compare extent of injury/area at risk versus previous reports as most studies do not include these data (36) .

Based on our results, fibroblast deletion of YAP provides benefit for ischemia-induced remodeling and does not alter the likelihood of cardiac rupture or death after MI (Supplemental Figure 6 ). However, this does not preclude the possibility that YAP may also have a reparative function post-MI, which might be apparent in the context of a larger infarct.

STUDY LIMITATIONS. We conducted this investigation in male mice. Sex differences in MI injury have been reported (37) . Verteporfin has been shown to effectively inhibit YAP-TEAD function in vivo; however, studies using TEAD1-deficient mice to rule out potential off-target effects would be ideal. 

Heart-Derived Hormones in Physiology and Disease Juanjuan Zhao, PHD, a Liming Pei, PHD a,b

The heart uses an endocrine mechanism to communicate with the rest of the body.

Heart-derived hormones, such as GDF-15, myostatin, and ANP/BNP, share common features, including synthesis, regulation, and function, and they coordinate the functions of the heart and target organs.

Additional heart-secreted factors play important autocrine and/or paracrine roles in local cardiac remodeling.

Future studies in the field of cardiac endocrinology will further advance the understanding of the intricate communications between the heart and the rest of the body.

The heart plays a central role in the circulatory system and provides essential oxygen, nutrients, and growth factors to the whole organism. The heart can synthesize and secrete endocrine signals to communicate with distant target organs.

Studies of long-known and recently discovered heart-derived hormones highlight a shared theme and reveal a unified mechanism of heart-derived hormones in coordinating cardiac function and target organ biology. This paper reviews the biochemistry, signaling, function, regulation, and clinical significance of representative heart-derived hormones, with a focus on the cardiovascular system. This review also discusses important and exciting questions that will advance the T he vital function of the heart has been known for thousands of years. The heart beats continuously to pump blood that carries oxygen and nutrients to every cell of our body. An unhealthy heart, such as one with heart failure, has significantly reduced contractile function that reduces its ability to perform such a task. As a result, cells in our body receive less oxygen, nutrients, and other factors critical for their survival, growth, and normal function. In contrast, during exercise, the heart needs to elevate its rate and capacity to satisfy the increased whole body oxygen and energy demand. Therefore, it is of paramount importance that the heart communicates its functional status to the rest of the body to coordinate nutritional needs and functions.

Such heart-derived signals can take many forms and can be neuronal or endocrine in nature. Neuronal signals tend to be fastacting, whereas endocrine signals can stimulate long-term changes. The heart can signal its functional status to the brain through sensory nerves; the brain then integrates and relays this information to the rest of the body through efferent nerves or endocrine signals (e.g., change in growth hormone level).

Alternatively, the heart can secrete signals into the circulation that travel to distant sites of the body to directly affect their biology, thus functioning as heart-derived hormones.

Such heart-derived hormones can be pro- . Therefore, we refer to the study of these heart-derived hormones in physiology and disease as cardiac endocrinology.

We review known heart-derived hormones, focusing on GDF15, myostatin, and ANP/BNP, and their biology in the cardiovascular system. We also briefly summarize additional heart-secreted factors with significant clinical relevance that largely function in an autocrine or paracrine manner to regulate local cardiac function. Last, we discuss important and exciting questions that remain to be answered in the field of cardiac endocrinology. can be secreted and that PCSK-mediated maturation can occur extracellularly (20, 21) . It remains to be discovered how circulating GDF-15 is cleared or degraded. Outside of the cardiovascular system, GDF-15 produces strong appetite-suppressing and nausea-like effects that are completely dependent on GFRAL (23) (24) (25) (26) 30, 31) and was proposed to mediate metformin's effect on body weight and energy balance (32, 33 

Myostatin is another member of the TGF-b superfamily and was first discovered through screening in a mouse skeletal muscle library (5). A well-established negative regulator of muscle mass, myostatin is primarily expressed in skeletal muscle (5) . Low levels of Similar to GDF-15, myostatin is synthesized as a prepro-protein, which then undergoes glycosylation and homodimerization via an intermolecular disulfide bond ( Figure 1A) . (48, 49) .

In the cardiovascular system, myostatin levels in both the heart and circulation are elevated in myocardial infarction or heart failure (50) (51) (52) (53) . The myostatin processing enzyme bone morphogenetic protein 1 activity was also increased in patient hearts with ischemic or dilated cardiomyopathy (52) . Clinical studies showed that plasma myostatin level was positively correlated with heart disease biomarker Nterminal pro-BNP in patients with congestive heart failure and with infarct size in acute myocardial infarction, which indicated that myostatin is a potential biomarker for these heart diseases.

Cachexia and muscle wasting are often observed in severe heart disease (e.g., heart failure).

Nkx2.5-creÀmediated, cardiac-specific deletion of Table 1 , and we focus our discussion on those with significant clinical relevance.

C-TYPE NATRIURETIC PEPTIDE. Unlike ANP and BNP, C-type natriuretic peptide (CNP) is widely expressed and not heart-specific (117, 118) . However, cardiac synthesis of CNP is substantially elevated in patients with chronic heart failure (79), and CNP regulates cardiac function through its receptor NPR-B in the heart (119-121). Cardiac-specific overexpression of CNP in rats had no effect on the infarct size upon ischemia/reperfusion injury but prevented the following hypertrophy (80) . Systemic infusion of CNP significantly reduced hypertrophy and fibrosis after myocardial infarction in mice (81) .

Cardiomyocyte-specific deletion of CNP showed deteriorated heart function in a pressure-overload injury model (82). Although both HIF-1a and HIF-2a can modulate the transcription of the same genes, the 2 isoforms often do so in an opposing manner (9, 10) . Thus, the ability of HIF-1a and HIF-2a to activate specific target genes is highly context-dependent, particularly with respect to the inciting stimulus and cell type (2) .

The activities of HIF-1a and HIF-2a are upregulated both by hypoxia and by drugs that mimic hypoxia under normoxic conditions (e.g., cobalt chloride) (4, 6, 11) . Oxygen influences the activity of these isoforms by directly modulating the activation of a family of 3 prolyl hydroxylases (PHD1, PHD2, and PHD3) that function to degrade the 2 transcription factors; the PHDs are sensitive to environmental oxygen, and thus, act as oxygen sensors (12) (13) (14) .

Inhibition of these PDHs by hypoxia leads to stabilization of one or both HIFs, which leads to enhanced HIF signaling. However, PHD1, PHD2, and PHD3 differ meaningfully with respect to their expression profiles, subcellular localization, and their effects on HIF-1a or HIF-2a (15, 16) .

Therefore, despite the structural homology of HIF-1a and HIF-2a, differences in cellular and subcellular expression patterns, upstream regulators, and sensitivity to degradative enzymes explain why HIF-1a and HIF-2a exert highly distinctive effects under a range of specific conditions. In general, HIF-1a

promotes the transcription of proteins that decrease oxygen use and increase angiogenesis, whereas HIF-2a

is the primary stimulus for erythropoietin synthesis (17, 18) . In addition, under conditions of prolonged cellular stress, HIF-1a and HIF-2a exert diametrically opposing actions on critical pathways that determine the balance between health and disease, especially in the development of chronic cardiac, vascular, and renal disorders (9,10). As a result, switching from the expression of one isoform to another appears to play a role in the pathogenesis of many diseases and may mediate the effects of treatment (19) . activation favors HIF-2a over HIF-1a, and SIRT1 has direct effects to preserve the integrity of mitochondria and peroxisomes similar to the actions of HIF-2a (40) . For these reasons, SIRT1 is poised to act as a HIF-1a to HIF-2a switch (19) .

Following an abrupt decline in oxygen tension, activation of HIF-1a and HIF-2a promotes the adaptation of the myocardium to hypoxia; HIF upregulation ameliorates ischemiaÀreperfusion injury, whereas HIF downregulation exacerbates hypoxic dysfunction (41) . Suppression of HIF-1a causes inadequate vascularization, and thus, decompensation of acute pressure overload or ischemic states (42) .

However, enhanced HIF-1a signaling may not be beneficial in chronic heart failure, which is characterized by oxidative stress and SIRT1 suppression ( Figure 2 ) (38) . The action of HIF-1a to shift glucose metabolism from oxidative to glycolytic pathways limits cardiac performance because glycolysis is an inefficient mechanism of generating adenosine triphosphate; this shift also promotes lipid The effects of hypoxia-inducible factor (HIF)-1a signaling to enhance adaption to acute hypoxia are immediate and short-lived, whereas the effects of HIF-1a signaling to promote oxidative stress, inflammation, and fibrosis are seen with sustained activation.

accumulation in cardiomyocytes, which leads to contractile dysfunction (43) . Moreover, HIF-1a impairs mitochondrial biogenesis, further limiting the generation of adenosine triphosphate (22) . HIF-1a can also promote hypertrophy and inflammation in cardiomyocytes (44) (45) (46) and may activate the sympathetic nervous system in chronic heart failure (47) .

For all of these reasons, marked, sustained, and isolated activation of HIF-1a acts to impair cardiac performance. Stabilization of HIF-1a at high levels leads to worsening myocardial function (48) , and genetic overexpression of HIF-1a results in cardiomyopathy (49) . Conversely, inhibition of HIF-1a slows the transition from cardiac hypertrophy to dilated cardiomyopathy (50) . Therefore, it is interesting that expression of HIF-1a is increased in the failing heart, both experimentally and clinically (48, 51) . High circulating levels of HIF-1a are associated with a poor prognosis in patients with chronic heart failure (52), and drugs that are effective in treating heart failure can diminish the activation of HIF-1a (53) .

In contradistinction to HIF-1a, activation of HIF-2a exerts protective effects in cardiomyocytes (54) The effects of HIF-1a signaling to promote oxidative stress, inflammation, and fibrosis are seen with sustained activation. Abbreviation as in Figure 1 . Although HIF-1a promotes inflammation, activation of HIF-2a mutes inflammation and reduces injury in renal tissues (68, 79) . Chronic kidney disease is characterized by upregulation of HIF-1a but downregulation of HIF-2a (30, 79, 80) , and the deficiency in HIF-2a likely explains why chronic kidney disease is accompanied by blunted production of erythropoietin and anemia (81) , and why impaired erythropoietin synthesis is accompanied by increased inflammatory and angiogenic markers (82) . The interplay between HIF-1a and HIF-2a may be particularly important in diabetes (78) , because hyperglycemia and advanced glycation end products directly promote the transcription of HIF-1a in glomerular and renal tubular cells (83, 84) . In addition, SIRT1

signaling (along with its ability to inhibit HIF-1a and activate HIF-2a) is impaired in the diabetic kidney (38, 39) . Similarly, sodium-glucose cotransporter 2 (SGLT2)

inhibitors that are used to treat type 2 diabetes have important cardioprotective and reno-protective effects, both experimentally and clinically (38, 39) .

These drugs appear to activate SIRT1 and its down- effects of SGLT2 inhibitors on SIRT1 signaling have been proposed to mediate their favorable effects on the heart and kidneys (38, 39) . SIRT1 upregulation may explain the effect of SGLT2 inhibitors to suppress HIF-1a in the kidney (98, 99) , as well as their effect to enhance the production of erythropoietin and promote erythrocytosis (100) (which is potentially related to SIRT1-mediated activation of HIF-2a37).

The importance of this latter effect is reinforced by the results of statistical mediation analyses, which showed that changes in hemoglobin produced by SGLT2 inhibitors are a powerful predictor of their ability to reduce the risk of cardiovascular death and hospitalizations for heart failure (101, 102) . 

Heart failure with preserved ejection fraction in perspective

Dissecting the benefits of sacubitril-valsartan for heart failure

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Sacubitril/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives

Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growthpromoting effects of norepinephrine in cardiac myocytes and fibroblasts

Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes

The role of natriuretic peptides in cardioprotection

Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model

Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs

Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides

Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction

Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone

LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice

Cardiac fibrosis in mice lacking brain natriuretic peptide

Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction

The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis

Genetic lineage tracing defines myofibroblast origin and function in the injured heart

Resident fibroblast expansion during cardiac growth and remodeling

The Hippo signal transduction network in skeletal and cardiac muscle

Hippo pathway in organ size control, tissue homeostasis, and cancer

NF2 activates Hippo signaling and promotes ischemia/ reperfusion injury in the heart

A functional interaction between Hippo-YAP signalling and FoxO1 mediates the oxidative stress response

Hippo pathway deficiency reverses systolic heart failure after infarction

Hippo pathway effector Yap promotes cardiac regenera

Efficient inducible Cre-mediated recombination in Tcf21 cell lineages in the heart and kidney

Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth

Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis

A transcriptomic and epigenomic comparison of fetal and adult human cardiac fibroblasts reveals novel key transcription factors in adult cardiac fibroblasts

Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction

Myocardinrelated transcription factor A and yes-associated protein exert dual control in G protein-coupled receptor-and RhoA-mediated transcriptional regulation and cell proliferation

Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury

Macrophage hypoxia signaling regulates cardiac fibrosis via

Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis

The Hippo pathway effector YAP controls mouse hepatic stellate cell activation

Yap/Taz deletion in Gli(þ) cell-derived myofibroblasts attenuates fibrosis

Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis

Fibroblast-specific TGF-beta-Smad2/3 signaling underlies cardiac fibrosis

A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo

MBNL1-mediated regulation of differentiation RNAs promotes myofibroblast transformation and the fibrotic response

Potentiation of serum response factor activity by a family of myocardin-related transcription factors

Actin dynamics control SRF activity by regulation of its coactivator MAL

Induction of the matricellular protein CCN1 through RhoA and MRTF-A contributes to ischemic cardioprotection

Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics

Heart disease and stroke statistics-2020 update: a report from the American Heart Association

Genetic lineage tracing defines myofibroblast origin and function in the injured heart

Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription

Blockade of fibroblast YAP attenuates cardiac fibrosis and dysfunction through MRTF-A inhibition

Mechanobiology of YAP and TAZ in physiology and disease

Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis

Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction

Linking actin dynamics and gene transcription to drive cellular motile functions

A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats

A new natriuretic peptide in porcine brain

Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic polypeptide

GDF15 is a heart-derived hormone that regulates body growth

Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily

PLAB, a novel placental bone morphogenetic protein

GDF15 provides an endocrine signal of nutritional stress in mice and humans

GDF15 is an inflammation-induced central mediator of tissue tolerance

non-ST-segment-elevation acute coronary syndrome

Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial

The propeptide of macrophage inhibitory cytokine (MIC-1), a TGF-beta superfamily member, acts as a quality control determinant for correctly folded MIC-1

PACE4 undergoes an oncogenic alternative splicing switch in cancer

The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome

The TGF-beta superfamily cytokine MIC

GDF15: secretory mechanisms facilitate creation of latent stromal stores

TGF-beta contamination of purified recombinant GDF15

GFRAL is the receptor for GDF15 and is required for the antiobesity effects of the ligand

GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates

The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL

Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15

Single-nucleus transcriptomic survey of cell diversity and functional maturation in postnatal mammalian hearts

The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury

GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation

GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice

GDF15 induces anorexia through nausea and emesis

Metformininduced increases in GDF15 are important for suppressing appetite and promoting weight loss

GDF15 mediates the effects of metformin on body weight and energy balance

Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum

Genetic studies of body mass index yield new insights for obesity biology

H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer

The haplotype of the growth-differentiation factor 15 gene is associated with left ventricular hypertrophy in human essential hypertension

Uniting GDF15 and GFRAL: therapeutic opportunities in obesity and beyond

The MIC-1/GDF15-GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases

Anorexia/cachexia of chronic diseases: a role for the TGF-beta family cytokine MIC-1/GDF15

Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct

Regulation of myostatin activity and muscle growth

Activation of latent myostatin by the BMP-1/ tolloid family of metalloproteinases

Identification of a novel pool of extracellular promyostatin in skeletal muscle

Transforming growth factor-beta family ligands can function as antagonists by competing for type II receptor binding

Myostatin mutation associated with gross muscle hypertrophy in a child

Induction of cachexia in mice by systemically administered myostatin

A genome-wide SNP-association study confirms a sequence variant (g. 66493737C>T) in the equine myostatin (MSTN) gene as the most powerful predictor of optimum racing distance for thoroughbred racehorses

Largescale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness

Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure

Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy

Myostatin activation in patients with advanced heart failure and after mechanical unloading

PCSK6-mediated corin activation is essential for normal blood pressure

Differential activation by atrial and brain natriuretic peptides of two different receptor guanylate cyclases

Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions

Successive action of meprin A and neprilysin catabolizes B-type natriuretic peptide

Endopeptidase-24.11 in human plasma degrades atrial natriuretic factor (ANF) to ANF(99-105/106-126)

Mechanical and neuroendocrine regulation of the endocrine heart

Decompensated heart failure is associated with reduced corin levels and decreased cleavage of pro-atrial natriuretic peptide

Neprilysin inhibitors: emerging therapy for heart failure

BNP and NT-proBNP as diagnostic biomarkers for cardiac dysfunction in both clinical and forensic medicine

Angiotensin-neprilysin inhibition versus enalapril in heart failure

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

A cardiac microRNA governs systemic energy homeostasis by regulation of MED13

MED13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver

Alteration of myocardial GRK2 produces a global metabolic phenotype

Increased plasma myostatin in heart failure

Growth differentiation factor-8 (gdf8)/myostatin is a predictor of troponin I peak and a marker of clinical severity after acute myocardial infarction

Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury

Myocardial production of C-type natriuretic peptide in chronic heart failure

Cardiomyocyte-restricted over-expression of Ctype natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice

C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction

C-type natriuretic peptide co-ordinates cardiac structure and function

C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target

Cardiac-derived CTRP9 protects against myocardial ischemia/ reperfusion injury via calreticulin-dependent inhibition of apoptosis

CTRP9 knockout exaggerates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy through inhibiting the LKB1/AMPK pathway

C1q-TNF-related protein-9 promotes cardiac hypertrophy and failure

Endogenous endothelin-1 is required for cardiomyocyte survival in vivo

Fibroblast growth factor 2 is an essential cardioprotective factor in a closedchest model of cardiac ischemia-reperfusion injury

Cardiacspecific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia

bFGF regulates autophagy and ubiquitinated protein accumulation induced by myocardial ischemia/ reperfusion via the activation of the PI3K/Akt/ mTOR pathway

Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction

Angiotensin II-induced cardiac hypertrophy and fibrosis are promoted in mice lacking Fgf16

Fibroblast growth factor 21 protects against cardiac hypertrophy in mice

Induction of cardiac FGF23/ FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease

The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation

Expression of follistatin-related genes is altered in heart failure

Follistatin-like 1 in chronic systolic heart failure: a marker of left ventricular remodeling

Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay

Cardiac myocyte-specific ablation of follistatinlike 3 attenuates stress-induced myocardial hypertrophy

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system

Myocardial pressure overload induces systemic inflammation through endothelial cell IL

Functions for the cardiomyokine, MANF, in cardioprotection, hypertrophy and heart failure

Circulating microRNAs are new and sensitive biomarkers of myocardial infarction

Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans

Use of circulating microRNAs to diagnose acute myocardial infarction

A secretion trap

The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure

Secreted Frizzled-related protein 3 (sFRP3) in acute coronary syndromes

CNP): a new member of natriuretic peptide family identified in porcine brain

Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system

Expression of C-type natriuretic peptide and of its receptor NPR-B in normal and failing heart

Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart

Expression of C-type natriuretic peptide and its receptor NPR-B in cardiomyocytes

Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload

Roles of FGF signals in heart development, health, and disease

The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study

Circulating fibroblast growth factor 21 is associated with diastolic dysfunction in heart failure patients with preserved ejection fraction

Serum FGF21 is associated with future cardiovascular events in patients with coronary artery disease

FGF21 contributes to neuroendocrine control of female reproduction

FGF21 is an endocrine signal of protein restriction

Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat

A dozen years of discovery: insights into the physiology and pharmacology of FGF21

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

Identification of serum soluble ST2 receptor as a novel heart failure biomarker

Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week

Exosomes derived from cardiomyocytes promote cardiac fibrosis via myocyte-fibroblast cross-talk

Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia

Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders Milton Packer, MD a,b HIGHLIGHTS HIF-1a and HIF-2a promote cellular adaptation to acute hypoxia, but during prolonged activation, these isoforms exert mutually antagonistic effects on the redox state and on proinflammatory pathways. Imbalances in HIF-1a and HIF-2a may contribute to the evolution and progression of chronic cardiac, vascular, and renal disorders. Selective activation of HIF-2a can be achieved with drugs that inhibit isoform-selective PHDs or that promote the redox sensor

SUMMARY Hypoxia-inducible factor (HIF)-1a and HIF-2a promote cellular adaptation to acute hypoxia, but during prolonged activation, these isoforms exert mutually antagonistic effects on the redox state and on proinflammatory pathways

Sustained HIF-1a signaling can increase oxidative stress, inflammation, and fibrosis, actions that are opposed by HIF-2a

Imbalances in the interplay between HIF-1a and HIF-2a may contribute to the progression of chronic heart failure, atherosclerotic and hypertensive vascular disorders, and chronic kidney disease. These disorders are characterized by activation of HIF-1a and suppression of HIF-2a, which are potentially related to mitochondrial and peroxisomal dysfunction and suppression of the redox sensor, sirtuin-1. Hypoxia mimetics can potentiate

Selective activation of HIF-2a can be achieved with drugs that: 1) inhibit isoform-selective prolyl hydroxylases (e.g., cobalt chloride and roxadustat); or 2) promote the actions of the redox sensor, sirtuin-1 (e.g., sodium-glucose cotransporter 2 inhibitors). Selective HIF-2a signaling through sirtuin-1 activation may explain the effect of sodiumglucose cotransporter 2 inhibitors to simultaneously promote erythrocytosis and ameliorate the development of cardiomyopathy and nephropathy

The author attests they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Basic to Translational Science author instructions page

Hypoxia-inducible factors in physiology and medicine

HIF-1 and HIF-2 transcription factors-similar but not identical

Inherent DNA-binding specificities of the HIF-1a and HIF-2a transcription factors in chromatin

Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha

Genomewide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts

Widespread hypoxia-inducible expression of

Expression of hypoxia-inducible transcription factors in developing human and rat kidneys

Prolonged hypoxia differentially regulates hypoxiainducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha

Opposite functions of HIF-a isoforms in VEGF induction by TGF-b1 under non-hypoxic conditions

Differential regulation of pulmonary vascular cell growth by hypoxia-inducible transcription factor-1a and hypoxia-inducible transcription factor-2a

Cobalt inhibits the interaction between hypoxiainducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha

The prolyl hydroxylase oxygen-sensing pathway is cytoprotective and allows maintenance of mitochondrial membrane potential during metabolic inhibition

Kinetic investigations of the role of factor inhibiting hypoxia-inducible factor (FIH) as an oxygen sensor

Nuclear oxygen sensing: induction of endogenous prolyl-hydroxylase 2 activity by hypoxia and nitric oxide

Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts

Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxiainducible factor

Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia

Differentiating the functional role of hypoxiainducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells

Passing the baton: the HIF switch

Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: a mechanism of O2 sensing

Multiple factors affecting cellular redox status and energy metabolism modulate hypoxia-inducible factor prolyl hydroxylase activity in vivo and in vitro

HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity

Hypoxia signaling pathways: modulators of oxygen-related organelles

Hif-2a promotes degradation of mammalian peroxisomes by selective autophagy

Mutual antagonism between hypoxia-inducible factors 1a and 2a regulates oxygen sensing and cardiorespiratory homeostasis

Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/-mice

Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2þ signaling, prolyl hydroxylases, and mTOR

Intermittent hypoxia degrades HIF-2alpha via calpains resulting in oxidative stress: implications for recurrent apnea-induced morbidities

Regulation of obesity and insulin resistance by hypoxia-inducible factors

The balance of

Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis

Hypoxia inhibits TNF-a-induced TSLP expression in keratinocytes

Hypoxia-inducible factor-1a contributes to the profibrotic action of angiotensin II in renal medullary interstitial cells

Differential roles of Sirt1 in HIF-1a and HIF-2a mediated hypoxic responses

Role of deranged energy deprivation signaling in the pathogenesis of cardiac and renal disease in states of perceived nutrient overabundance

Role of impaired nutrient and oxygen deprivation signaling and deficient autophagic flux in diabetic CKD development: implications for understanding the effects of sodium-glucose cotransporter 2-inhibitors

Sirt1 and the mitochondria

Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury

Endothelial expression of hypoxia-inducible factor 1 protects the murine heart and aorta from pressure overload by suppression of TGF-b signaling

Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy

Chronic intermittent hypoxia induces cardiac inflammation and dysfunction in a rat obstructive sleep apnea model

Propofol alleviates apoptosis induced by chronic high glucose exposure via regulation of HIF-1a in H9c2 cells

Hypoxiainduced mitogenic factor promotes cardiac hypertrophy via calcium-dependent and hypoxiainducible factor-1a mechanisms

Hypoxia-inducible factor-1a mediates increased sympathoexcitation via glutamatergic N-Methyl-d-aspartate receptors in the paraventricular nucleus of rats with chronic heart failure

Unfavourable consequences of chronic cardiac HIF-1a stabilization

Conditional HIF-1alpha expression produces a reversible cardiomyopathy

Canopy 2 attenuates the transition from compensatory hypertrophy to dilated heart failure in hypertrophic cardiomyopathy

Myocardial expression of macrophage migration inhibitory factor in patients with heart failure

Admission hypoxiainducible factor 1a levels and in-hospital mortality in patients with acute decompensated heart failure

Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure

Hypoxia-inducible factor-2alpha transactivates Abcg2 and promotes cytoprotection in cardiac side population cells

Maladaptive modulations of NLRP3 inflammasome and cardioprotective pathways are involved in diet-induced exacerbation of myocardial ischemia/ reperfusion injury in mice

Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and stromal cells of ischemic myocardium

HIF-1a is required for disturbed flow-induced metabolic reprogramming in human and porcine vascular endothelium

Smooth muscle hypoxia-inducible factor 1a links intravascular pressure and atherosclerosis-brief report

Hypoxia-inducible factor-1a expression in macrophages promotes development of atherosclerosis

Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells

Positive cross-talk between hypoxia inducible factor-1a and liver X receptor a induces formation of triglyceride-loaded foam cells

Role of macrophage-derived hypoxia-inducible factor (HIF)-1a as a mediator of vascular remodelling

Hypoxia inducible factor-1: regulation by nitric oxide in posthypoxic microvascular endothelium

Vascular wall hypoxia promotes arterial thrombus formation via augmentation of vascular thrombogenicity

Adipocyte hypoxia-inducible factor 2a suppresses atherosclerosis by promoting adipose ceramide catabolism

OxLDL and macrophage survival: essential and oxygenindependent involvement of the Hif-pathway

HIF-2a and Oct4 have synergistic effects on Death Dis

Endothelial HIF-2 mediates protection and recovery from ischemic kidney injury

HIF-1a induction during reperfusion avoids maladaptive repair after renal ischemia/reperfusion involving miR127-3p

Stable expression of hypoxia-inducible factor-1a in human renal proximal tubular epithelial cells promotes epithelial to mesenchymal transition

HIF-1a inducing

Hypoxia-inducible factor-1a promotes glomerulosclerosis and regulates COL1A2 expression through interactions with Smad3

Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis

Selective tubular activation of hypoxia-inducible factor-2a has dual effects on renal fibrosis

Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney

The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia

Impaired erythropoietin synthesis in chronic kidney disease is caused by alterations in extracellular matrix composition

Advanced glycated end-products affect HIFtranscriptional activity in renal cells

High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein

Differential regulation of HIF-1 alpha prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells

Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors

Hypoxiainducible factor (HIF)-prolyl hydroxylase 3 (PHD3) maintains high HIF2A mRNA levels in clear cell renal cell carcinoma

JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, stabilizes HIF-a protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor

The role of metformin and resveratrol in the prevention of hypoxiainducible factor 1a accumulation and fibrosis in hypoxic adipose tissue

Sirt1-hypoxiainducible factor-1a interaction is a key mediator of tubulointerstitial damage in the aged kidney

Mir-217 promotes inflammation and fibrosis in high glucose cultured rat glomerular mesangial cells via Sirt1/HIF-1a signaling pathway

Resveratrol attenuates acute hypoxic injury in cardiomyocytes: correlation with inhibition of iNOS-NO signaling pathway

Resveratrol ameliorates the components of hepatic inflammation and apoptosis in a rat model of streptozotocin-induced diabetes

SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms

Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats

Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules

Hypoxia-inducible factor-1a is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial

Warped speed: how COVID-19 transfected and transformed medical journals

What and who are medical journals for?

Introducing JACC: Basic to Translational Science: Why now?

Sabri A Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload

Figures 6 and 7 have been replaced due to the following errors: In Figure 6, the original panel 6D was spliced. The splicing was not properly indicated in the figure, nor acknowledged in the text. Correction: Panel 6D now shows full uncut gels for collagen III

Interstitial Fibrosis, but not Perivascular Fibrosis

Scale Bar: 100 mm. (B, C) Summary results for myocardial fibrosis area (B) and perivascular fibrosis area (C) (n ¼ 5 each group). (D, E) (Top) Representative immunoblot analysis of sham and TAC hearts. (Bottom) Quantification of experiments represented as fold change compared to untreated sham normalized to GAPDH (n ¼ 5 each group). (F) MMP2/9 activity in the left ventricle of sham and TAC mice treated with vehicle or rivaroxaban as determined by enzymatic activity assay. Results are expressed as RFU/min/mg protein (n ¼ 5 for each group). Values are presented as mean AE SEM

CTGF ¼ connective tissue growth factor

TGF ¼ transforming growth factor

TIMP ¼ tissue inhibitor of metalloprotease

The splicing was not properly indicated in the figure, nor acknowledged in the text. Correction: Panel 7A summarizes the results from 3 different Western blots. The revised panel 7A shows full uncut gels SM a-actin and GAPDH loading control lanes (upper panel) and for

The areas of the gel that were cut are indicated with thin black lines, and the splicing is acknowledged in the text. Also in Figure 7, the original Figure 7E mistakenly used the GAPD loading control lane from panel 7E. Correction: Panel 7E now has the correct ERK loading control lane. The group data for panel 7E have been recalculated using the appropriate ERK loading control lane and are now shown in the right-hand side of panel 7E. The revised data analysis is similar to the original analysis of the group data and did not change the original interpretation of the findings in the original submission. The figure legend for Figure 7 has also been changed

The online version of the article has been corrected to reflect these changes

FIGURE 7 FXa Induces Fibroblast Proliferation, Migration and Differentiation Through

5 mM) or vehicle for 15 min and then treated with FXa (100 nM) or thrombin (Thr., 1 U/ml) for 36 h and cell lysates were processed for immunoblot analysis. Left: Representative immunoblots for SM a-actin (upper panel), TGF-b1 (middle panel) and Col. I (lower panel). GAPDH was included as a loading control. The gel for TGF-b1 and the GAPDH loading control was spliced from the same gel exposure. The areas of the gel that were spliced are indicated with thin black lines. Right: Quantification of experiments represented as fold change compared to untreated control (Ctrl). (B) Migration scratch assay was performed to assess the rate of migration of cardiac fibroblasts untreated or treated with FXa or thrombin without or with rivaroxaban pretreatment

FXa-and thrombin-treated fibroblasts compared with controls which was attenuated by rivaroxaban treatment. Scale bar: 200 mm. (E) Increased phosphorylation of

but not PAR2 antagonist GB83. (F and G) Improved migration and proliferation in FXa-and thrombin-treated cardiac fibroblasts were reduced by SCH79797, as counted from wound-scratch assays

sFRP2Antagonist of Wnt signaling MI (113, 114) sFRP3Antagonist of Wnt signaling HF, MI, ACS (115, 116)